Eton Pharmaceuticals relaunches HEMANGEOL with exclusive pharmacy and patient support for infantile hemangioma treatment

Eton Pharmaceuticals has relaunched HEMANGEOL, the only FDA-approved oral solution for treating infantile hemangiomas, through exclusive distribution by Anovo Specialty Pharmacy. The relaunch includes integrated patient support via Eton Cares, offering $0 co-pay for eligible patients and expanded assistance programs to ensure timely therapy initiation. Infantile hemangiomas are rare vascular tumors in infants requiring early treatment to prevent complications, making streamlined access critical. Eton aims to improve patient outcomes and family support with this focused specialty pharmacy model and comprehensive care services.